Skip to main content


Table 3 Oncotype DX, Prosigna, and Ellen performance

From: The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

  LN- Patients LN+ Patients
  p value Concordance p value Concordance
Oncotype DX 1.26E-04 0.78 3.06E-01 0.58
Prosigna 8.07E-04 0.79 1.34E-02 0.62
Ellen 1.27E-06 0.85 1.74E-04 0.71